Signal Genetics, a predictive genetic testing company focused on oncology, recently announced that it would work with pharmaceutical company Array BioPharma to advance both companies’ goals of finding biomarkers for myeloma patients.
All told, the Los Angeles-based company could have six to eight trials running simultaneously in the coming months.
“Programmed cell death” sounds a bit sinister, but it’s actually a normal and healthy process.
The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.
Keryx Biopharmaceuticals, Inc. is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA.
Onyx Pharmaceuticals has agreed to purchase private biotechnology company Proteolix for $276 million in cash.